Adopting early noninvasive cardiac testing is a cost-effective strategy for avoiding a future heart attack or death in patients with suspected acute coronary syndrome, according to a study published May 24 in Academic Emergency Medicine.
Researchers conducted a retrospective analysis of 89,387 Kaiser Permanente Southern California patients to examine care costs and quality-adjusted life-years associated with early noninvasive cardiac testing.
Here are five notes from the study:
- Of the 89,387 patients included in the study, 19% received early noninvasive cardiac testing.
- Total care costs were higher by $2,357 for patients who received early noninvasive cardiac testing compared to patients who did not. The higher costs were mainly attributed to the patient’s initial emergency department visit.
- In a one-year follow-up, patients who received early noninvasive cardiac testing had a 3.7% lower composite risk of nonfatal heart attack or death.
- Researchers determined that early noninvasive cardiac testing was cost-effective at $5,268 per quality-adjusted life-years.
- “Due to the significant clinical benefits, early noninvasive cardiac testing [is] cost-effective in the low- and intermediate-risk patients [and] a dominant strategy in high-risk patients saving cost and quality-adjusted-life-years,” the study authors wrote.
Read the full study here.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
